Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03957876 · ClinicalTrials.gov registry record · Phase 2
CPX-351 Therapy for MDS After Hypomethylating Agent Failure
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03957876 is a Phase 2 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 4 participants.
The verdict
NCT03957876, a Phase 2 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of treatment with CPX-351 (an FDA approved drug for the treatment of AML) in individuals with MDS while using a new stratification tool to predict outcomes of participants following HMA failure. This approach is intended to gain a better understanding and insight into identifying new opportunities for drug approvals in this setting.
Interventions
- DRUG CPX-351
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2022-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03957876
The ClinicalTrials.gov registry entry for NCT03957876 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CPX-351 is the first listed.
NCT03957876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03957876 about?
NCT03957876 is a clinical study titled "CPX-351 Therapy for MDS After Hypomethylating Agent Failure". The purpose of this study is to evaluate the efficacy of treatment with CPX-351 (an FDA approved drug for the treatment of AML) in individuals with MDS while using a new stratification tool to predict outcomes of participants following HMA failure. This approach is intended to gain a better understa...
What is the current status of trial NCT03957876?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-07-25. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT03957876?
The interventions under investigation include: CPX-351 (DRUG).
Who is sponsoring clinical trial NCT03957876?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.